Skip to search
Skip to main content
Back to Search
Start Over
Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.
Authors :
Javle, Milind M. Roychowdhury, Sameek Kelley, Robin Kate Sadeghi, Saeed Macarulla, Teresa Waldschmidt, Dirk Thomas Goyal, Lipika Borbath, Ivan El-Khoueiry, Anthony B. Yong, Wei-Peng Philip, Philip Agop Bitzer, Michael Tanasanvimon, Suebpong Pande, Amit Shepherd, Stacie Peacock Moran, Susan Abou-Alfa, Ghassan K. Javle, Milind M. Roychowdhury, Sameek Kelley, Robin Kate Sadeghi, Saeed Macarulla, Teresa Waldschmidt, Dirk Thomas Goyal, Lipika Borbath, Ivan El-Khoueiry, Anthony B. Yong, Wei-Peng Philip, Philip Agop Bitzer, Michael Tanasanvimon, Suebpong Pande, Amit Shepherd, Stacie Peacock Moran, Susan Abou-Alfa, Ghassan K.
Publication Year :
2021
Details
Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1312208056
Document Type :
Electronic Resource